Cellosaurus logo
expasy logo

Cellosaurus K562/FLM (CVCL_E7CM)

[Text version]
Cell line name K562/FLM
Accession CVCL_E7CM
Resource Identification Initiative To cite this cell line use: K562/FLM (RRID:CVCL_E7CM)
Comments Population: Caucasian.
Characteristics: Resistant to about 50 nmol/L of flumatinib. Also resistant to imatinib and doxorubicin (PubMed=39046364).
Selected for resistance to: ChEBI; CHEBI_233593; Flumatinib.
Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (PubMed=39046364).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
Disease Blast phase chronic myelogenous leukemia, BCR-ABL1 positive (NCIt: C9110)
Chronic myeloid leukemia (ORDO: Orphanet_521)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0004 (K-562)
Sex of cell Female
Age at sampling 53Y
Category Cancer cell line
Publications

PubMed=39046364; DOI=10.1111/jcmm.18539; PMCID=PMC11267979
Ji-Xian Huang, Jie Xiao, Li-Feng He, Wen-Jie Dai, Jian Xiao, Yu-Quan Li, Ying He, Liang Yu;
Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential.
J. Cell. Mol. Med. 28:e18539.1-e18539.10(2024)

Entry history
Entry creation10-Apr-2025
Last entry update10-Apr-2025
Version number1